Marijuana Ordering Kiosks For Seniors Present Both Opportunities And Risks (Op-Ed)

“Kiosk-based cannabis access for seniors can be a positive development only if it is embedded within a medically supervised, ethically structured care model.”

By Jordan Tishler, Association of Cannabinoid Specialists

A company recently declared its intention to roll out cannabis ordering kiosks in several senior-life communities in Arizona.

The general idea is that residents would gain easier access to cannabis by being able to order products on the kiosk and have the product delivered right to them—kind of like online ordering but without needing a computer. But without appropriate safeguards for medical and non-medical users alike, the risk of this scheme may outweigh the benefit of greater access.

The Association of Cannabinoid Specialists (ACS) strongly supports efforts to reduce access barriers for older adults who may benefit from cannabinoid-based therapies, especially those with limited transportation and mobility.

A guided ordering interface that reinforces clinician-based treatment plans (aka prescriptions), clear product information and licensed dispensary sourcing is far preferable to unregulated or informal supply channels that some seniors might currently rely on.

However, simply placing cannabis kiosks in independent living communities without robust clinical safeguards is not acceptable from a specialist perspective.

Older adults typically have multiple comorbidities, complex polypharmacy and age-related changes in metabolism and cognition that substantially increase the risk of adverse events, drug–drug interactions and delirium. Furthermore, access to cannabis without clinical guidance leads to increased risk of misuse, dependence or addiction.

Introducing a point-of-sale educational experience, even one described as “guided,” is not a substitute for individualized medical assessment, diagnosis and ongoing monitoring by clinicians trained in cannabinoid medicine.

ACS welcomes the stated focus on education and clear product information at the point of ordering, including helping residents understand different product types, routes of administration and onset/duration profiles. But education delivered via kiosks or brand-affiliated educators remains inherently product- and transaction-centric, whereas proper cannabinoid care must be patient- and diagnosis-centric, integrated into the person’s full medical history, medication list and goals of care.

For seniors, dose-finding, titration schedules, contraindications and deprescribing decisions cannot responsibly be handled through a consumer-facing digital interface.

If cannabis kiosks are to be deployed in senior living communities, ACS believes the following elements are essential:

• Formal collaboration with the resident’s medical team, including communication of products, doses and changes over time, and documentation in the medical record.

• Access to qualified cannabinoid-trained clinicians (physicians, NPs) for pre-initiation assessment and ongoing follow-up, not just sales or brand educators.

• Clear protocols for referring both medical and non-medical users to, or back to, qualified clinicians for guidance and follow-up, particularly to screen for high-risk users and drug interactions, and to appropriately recommend and titrate regimens for older individuals.

• Transparent separation between clinical guidance and commercial interests, including clear disclosure of financial relationships and avoidance of quota-driven or upselling practices.

Without these safeguards, the convenience and revenue opportunity described for dispensaries and communities risk outpacing appropriate clinical governance and patient safety protections.

From ACS’s point of view, kiosk-based cannabis access for seniors can be a positive development only if it is embedded within a medically supervised, ethically structured care model.

We encourage senior living operators, technology vendors and dispensaries to partner with cannabinoid medicine specialists to design programs where improved access and education are matched by rigorous clinical oversight, documentation and responsibility for outcomes.

Jordan Tishler, MD is the president of the Association of Cannabinoid Specialists.